Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
about
Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene clusterC-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancerLong-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testingPolysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cellsComputer-assisted assessment of the human epidermal growth factor receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls.Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.Immunohistochemistry as an important tool in biomarkers detection and clinical practice.Utilization of HER2 genetic testing in a multi-institutional observational study.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expressionElevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancerErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependencyIncreased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based studyErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic ImplicationsAddition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patientsTesting for HER2 in Breast Cancer: A Continuing Evolution.Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.Estrogen receptor-negative breast ductal carcinoma: clinicopathological features and MIB-1 (Ki-67) proliferative index associationThe Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with HerceptinT lymphocyte density and distribution in human colorectal mucosa, and inefficiency of current cell isolation protocols.Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PETImmunohistochemical study of the expression of MUC5AC and MUC6 in breast carcinomas and adjacent breast tissues.Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades.PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.HER2 evaluation and its impact on breast cancer treatment decisions.IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival.Mouse mammary gland is refractory to the effects of ethanol after natural lactation.Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer.Prognostic significance of HER2 gene amplification according to stage of breast cancerExpression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancerFGFR1 is amplified during the progression of in situ to invasive breast carcinomaAssessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival.The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer.Near-infrared quantum dots for HER2 localization and imaging of cancer cells.Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates.
P2860
Q24670351-4A60AEC2-32C1-432A-9DF7-D618C48BC7A2Q24795406-252803CB-6A98-41C4-931A-845BACFBDAC3Q24797752-D7055245-5390-4263-9E52-311F198FCF06Q24797806-C2A634AA-01C3-4703-A595-71F377CC4523Q25257668-1E82C95F-7143-46A3-8456-DA85AB30BE1CQ30482618-EFD5D97D-2DA0-4953-B267-C557F8C0DE1AQ33661325-FCAFA4C1-78B7-4DE7-823E-5F09B249CAE1Q33704442-F3D24BAA-0C58-4CFC-809E-1AFEEEADBD4AQ33771243-DB84F823-911C-48FB-9E03-285D343D0DC5Q33807542-878E4624-1289-49B7-8298-FF6FA6C4F07EQ33829405-D58AFC60-6DA9-4DBD-916C-4F6C7B4E783DQ33890758-966F6903-7A53-4007-BFB1-B1FD3A76A4D7Q33963261-B0752A8B-A50B-4470-944A-555AC13B7AC7Q34129444-121CBD10-02E9-4F9C-932E-790585804062Q34133760-54352BCF-43AF-4681-8378-ADE42E99413FQ34223494-49E41D94-9E0C-4BEB-B1A6-85C336AD3DA2Q34344146-29555403-1D16-4D40-BA56-12D825F61D5BQ34424285-79666B97-8BBB-4BBE-A262-6BB159BABC1FQ35038093-140BF30F-0839-4F52-A2FE-7B31794D6D3CQ35106790-A120E9DB-CA5E-4A68-8E30-6997BDC23B5CQ35184360-5A081F55-8A4E-4B0F-950D-28A9C5A4BD64Q35344900-7CC97C4C-43B9-440F-84B0-546E0EC30D78Q35350578-4766AB3F-4B3F-4AFB-BFB5-6CABB2A38D19Q35398324-18A11F0A-0BDE-41C2-9088-5DB660947D57Q35440615-00BB7803-94D2-419C-AC63-EEFB483A3ED5Q35562967-FA052A49-BF4F-41A6-929E-B62C75AD5296Q35576343-B19DCC29-2B78-48C7-9734-CC01DECB9A9BQ35588768-4472FCFF-79D4-43D9-ADB5-3AB4F4611301Q36421775-7003F3E3-E643-481C-ADBD-9488615CD16BQ36595433-1D4D9BDC-76C6-4889-98BC-179C3324325CQ36617556-DA9F63B4-3776-4087-9A47-9D29763F0120Q36854475-BE6CA210-26D6-4A2E-97A8-42C9AFF02606Q36898399-2CBA87CB-F9D7-4E1E-BEA4-5B08B9ABC26BQ36924421-1D7634AC-3F17-4DF9-884B-B6A0D550EDAAQ36950483-DA2C0AAC-54F3-4906-AFB7-834198A91E69Q37165239-686D27C0-9FAC-444F-BFB4-9D1C7EEEC0DFQ37326072-7B842A90-A19F-461B-8DD3-4E44B6993B7CQ37419479-8C41D380-FDE6-450F-B425-99D60393D613Q37641853-86C0FBB0-D8DB-4FD2-B9A9-9B11D9F56E12Q37641886-D1B7B23B-5C7E-4B11-B5D2-4FAE8574C073
P2860
Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Her-2/neu expression in node-n ...... sed risk of recurrent disease.
@en
type
label
Her-2/neu expression in node-n ...... sed risk of recurrent disease.
@en
prefLabel
Her-2/neu expression in node-n ...... sed risk of recurrent disease.
@en
P2093
P1433
P1476
Her-2/neu expression in node-n ...... ased risk of recurrent disease
@en
P2093
Markowicz M
Sliwkowski M
P304
P407
P50
P577
1993-10-01T00:00:00Z